Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1086131

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1086131

Monoclonal Antibodies Market, by Source, by Application, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

PUBLISHED:
PAGES: 335 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4500
PDF (Multi User License)
USD 7000
PDF (Enterprise User License)
USD 10000

Add to Cart

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.

Market Dynamics

Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.

Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2021 in Europe.

Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Key features of the study:

  • This report provides in-depth analysis of the global monoclonal antibodies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global monoclonal antibodies market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future launches, market expansion, and marketing tactics
  • The global monoclonal antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibodies market

Detailed Segmentation:

  • Global Monoclonal Antibodies Market, By Source:
  • Human
  • Chimeric
  • Murine
  • Humanized
  • Global Monoclonal Antibodies Market, By Application:
  • Cancer
  • Autoimmune Disease
  • Hematological Disease
  • Infectious Disease
  • Others
  • Global Monoclonal Antibodies Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Monoclonal Antibodies Market, By Region:
  • North America

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country:

? U.S.

? Canada

  • Latin America

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country:

? Brazil

? Mexico

? Argentina

? Rest of Latin America

  • Europe

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country:

? Germany

? U.K.

? France

? Italy

? Spain

? Russia

? Rest of Europe

  • Asia Pacific

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country:

? China

? India

? Japan

? Australia

? South Korea

? ASEAN

? Rest of Asia Pacific

  • Middle East

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country:

? GCC

? Israel

? Rest of Middle East

  • Africa

? By Source:

? Human

? Chimeric

? Murine

? Humanized

? By Application:

? Cancer

? Autoimmune Disease

? Hematological Disease

? Infectious Disease

? Others

? By Distribution Channel:

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country/Region:

? South Africa

? Central Africa

? North Africa

  • Company Profiles
  • Pfizer Inc.*

? Company Overview

? Product Portfolio

? Financial Performance

? Key Highlights

? Market Strategies

  • Novartis AG
  • Bayer AG
  • Sanofi S.A.
  • Hoffmann-La Roche AG
  • Eli Lilly and Co.
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc.
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI2403

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Source
    • Market Snippet, By Therapeutic Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
  • Technological Evolution
  • PEST Analysis
  • Pipeline Analysis
  • Porter's Analysis

4. Global Monoclonal Antibody Therapeutics Market, By Source, 2017 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Human
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Humanized
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Chimeric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

5. Global Monoclonal Antibody Therapeutics Market, By Therapeutic Application, 2017 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Autoimmune Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Infectious Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Hematological Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Monoclonal Antibody Therapeutics Market, By Distribution Channel, 2017 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Monoclonal Antibody Therapeutics Market, By Regions, 2017 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2030
  • North America
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Source, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffman-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eily, Lilly, and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!